The high prevalence of LATE among individuals with AD – estimated at up to 50% of advanced AD (Braak stage V–VI) in community‐based autopsy cohorts13 – limits attribution of atrophy and clinical symptoms solely to AD pathology, given that standard biomarkers capture amyloid and tau but not TDP‐43 pathology. This evidence concerns the gene MAPT and Alzheimer disease.